Terms: = Endocrine gland cancer AND GNA11, GNA-11, 2767, ENSG00000088256
27 results:
1. Double somatic mutations in
Nanba K; Blinder AR; Udager AM; Hirokawa Y; Miura T; Okuno H; Moriyoshi K; Yamazaki Y; Sasano H; Yasoda A; Satoh-Asahara N; Rainey WE; Tagami T
Front Endocrinol (Lausanne); 2024; 15():1286297. PubMed ID: 38505749
[TBL] [Abstract] [Full Text] [Related]
2. Development and Validation of a Nomogram Based on Multimodality Ultrasonography Images for Differentiating Malignant from Benign American College of Radiology Thyroid Imaging, Reporting and Data System (TI-RADS) 3-5 Thyroid Nodules.
Pang L; Yang X; Zhang P; Ding L; Yuan J; Liu H; Liu J; Gong X; Yu M; Luo W
Ultrasound Med Biol; 2024 Apr; 50(4):557-563. PubMed ID: 38262884
[TBL] [Abstract] [Full Text] [Related]
3. Genetic and clinical screening for hereditary primary hyperparathyroidism in a large Chinese cohort: a single-center study.
Song A; Yang Y; Jiang Y; Nie M; Jiang Y; Li M; Xia W; Xing X; Wang O
J Bone Miner Res; 2023 Sep; 38(9):1322-1333. PubMed ID: 37449924
[TBL] [Abstract] [Full Text] [Related]
4. Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders.
Canaff L; Guarnieri V; Kim Y; Wong BYL; Nolin-Lapalme A; Cole DEC; Minisola S; Eller-Vainicher C; Cetani F; Repaci A; Turchetti D; Corbetta S; Scillitani A; Goltzman D
Eur J Endocrinol; 2022 Feb; 186(3):351-366. PubMed ID: 35038313
[TBL] [Abstract] [Full Text] [Related]
5. Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.
Colombo D; Gatti L; Sjöstrand L; Carenini N; Costantino M; Corna E; Arrighetti N; Zuccolo M; De Cesare M; Linder S; D'Arcy P; Perego P
Biochem Pharmacol; 2022 Mar; 197():114900. PubMed ID: 34995485
[TBL] [Abstract] [Full Text] [Related]
6. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.
Brown ZJ; Labiner HE; Shen C; Ejaz A; Pawlik TM; Cloyd JM
J Surg Oncol; 2022 Feb; 125(2):185-193. PubMed ID: 34599756
[TBL] [Abstract] [Full Text] [Related]
7. Somatic mutations of gna11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause.
Zhou J; Azizan EAB; Cabrera CP; Fernandes-Rosa FL; Boulkroun S; Argentesi G; Cottrell E; Amar L; Wu X; O'Toole S; Goodchild E; Marker A; Senanayake R; Garg S; Åkerström T; Backman S; Jordan S; Polubothu S; Berney DM; Gluck A; Lines KE; Thakker RV; Tuthill A; Joyce C; Kaski JP; Karet Frankl FE; Metherell LA; Teo AED; Gurnell M; Parvanta L; Drake WM; Wozniak E; Klinzing D; Kuan JL; Tiang Z; Gomez Sanchez CE; Hellman P; Foo RSY; Mein CA; Kinsler VA; Björklund P; Storr HL; Zennaro MC; Brown MJ
Nat Genet; 2021 Sep; 53(9):1360-1372. PubMed ID: 34385710
[TBL] [Abstract] [Full Text] [Related]
8. Gα15 in early onset of pancreatic ductal adenocarcinoma.
Innamorati G; Wilkie TM; Malpeli G; Paiella S; Grasso S; Rusev B; Leone BE; Valenti MT; Carbonare LD; Cheri S; Giacomazzi A; Zanotto M; Guardini V; Deiana M; Zipeto D; Serena M; Parenti M; Guzzi F; Lawlor RT; Malerba G; Mori A; Malleo G; Giacomello L; Salvia R; Bassi C
Sci Rep; 2021 Jul; 11(1):14922. PubMed ID: 34290274
[TBL] [Abstract] [Full Text] [Related]
9. Determination of Potential Therapeutic Targets and Prognostic Markers of Ovarian cancer by Bioinformatics Analysis.
Zhang J; Huang S; Quan L; Meng Q; Wang H; Wang J; Chen J
Biomed Res Int; 2021; 2021():8883800. PubMed ID: 33829065
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
[TBL] [Abstract] [Full Text] [Related]
11. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract] [Full Text] [Related]
12. Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.
Marx SJ; Goltzman D
J Bone Miner Res; 2019 Jan; 34(1):22-37. PubMed ID: 30536424
[TBL] [Abstract] [Full Text] [Related]
13. Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data.
Lu X; Lu J; Liao B; Li X; Qian X; Li K
Sci Rep; 2017 Nov; 7(1):16188. PubMed ID: 29170526
[TBL] [Abstract] [Full Text] [Related]
14. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract] [Full Text] [Related]
15. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract] [Full Text] [Related]
16. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.
Corno C; Gatti L; Arrighetti N; Carenini N; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2017 Jul; 136():40-50. PubMed ID: 28404378
[TBL] [Abstract] [Full Text] [Related]
17. Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.
Pfankuchen DB; Stölting DP; Schlesinger M; Royer HD; Bendas G
Biochem Pharmacol; 2015 Sep; 97(2):147-57. PubMed ID: 26239805
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathological correlates of hyperparathyroidism.
Duan K; Gomez Hernandez K; Mete O
J Clin Pathol; 2015 Oct; 68(10):771-87. PubMed ID: 26163537
[TBL] [Abstract] [Full Text] [Related]
19. Metastatic disease in uveal melanoma: importance of a genetic profile?
Van Beek JG; Koopmans AE; Vaarwater J; Verdijk RM; de Klein A; Naus NC; Kiliç E
Melanoma Res; 2015 Oct; 25(5):447-9. PubMed ID: 26086698
[TBL] [Abstract] [Full Text] [Related]
20. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract] [Full Text] [Related]
[Next]
